| Zacks Company Profile for NovaBay Pharmaceuticals, Inc. (NBY : AMEX) |
|
|
| |
| • Company Description |
| NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus.
Number of Employees: 14 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.65 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 20,765 shares |
| Shares Outstanding: 5.82 (millions) |
| Market Capitalization: $3.78 (millions) |
| Beta: 0.44 |
| 52 Week High: $2.45 |
| 52 Week Low: $0.36 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
0.95% |
-2.83% |
| 12 Week |
8.28% |
-8.92% |
| Year To Date |
8.10% |
1.24% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Justin Hall - Chief Executive Officer; General Counsel and Direc
Paul E. Freiman - Chairman of the Board
Tommy Law - Interim Chief Financial Officer
Julie Garlikov - Director
Swan Sit - Director
|
|
Peer Information
NovaBay Pharmaceuticals, Inc. (GSAC)
NovaBay Pharmaceuticals, Inc. (CASI)
NovaBay Pharmaceuticals, Inc. (ALCD.)
NovaBay Pharmaceuticals, Inc. (OMNN)
NovaBay Pharmaceuticals, Inc. (CGPI.)
NovaBay Pharmaceuticals, Inc. (CATX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 66987P409
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
|
|
Share - Related Items
Shares Outstanding: 5.82
Most Recent Split Date: 5.00 (0.03:1)
Beta: 0.44
Market Capitalization: $3.78 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.21 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.86 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 08/12/25 |
|
|
|
| |
